HBOT Packages. Capacity-limited protocol products, never a recurring membership.
Clinical-grade hyperbaric oxygen at 2.0+ ATA — the pressure regime the longevity literature uses — sold as protocol packages, 12-session blocks, or single sessions. Not a membership: chamber capacity is hard-capped at roughly twelve full 60-session protocols per year, so subscription-style access cannot be honoured. Protocols are sold in cohort windows with confirmed start dates rather than always-on, so chamber demand can be managed against capacity.
Capacity is the binding constraint, and capacity sets the product.
Hyperbaric oxygen at clinical-grade 2.0+ ATA pressure is the pressure regime the Efrati longevity literature uses — the studies showing telomere lengthening and senescent cell reduction in older adults all depend on completion of a 60-session protocol delivered at sustained 2.0 ATA, five sessions per week for twelve weeks. The clinical product is the full protocol; partial dosing does not produce the biomarker effects the literature describes.
A monoplace HBOT chamber operating eight hours a day, six days a week, on 75-minute slots (60-minute session plus 15 minutes of decompression check, chamber wipe-down, brief, and pre-session checklist) delivers approximately 36 sessions per week, or 1,800 sessions per year on 50 operating weeks. A full protocol consumes 60 sessions across 12 weeks at five sessions per week — five weekly slots per protocol customer for the duration of the protocol period. Three concurrent cohorts at staggered start dates (one 4 weeks in, one 8 weeks in, one just starting) consumes 15 sessions per week and produces a new protocol completion every 4 weeks. With 50 operating weeks and a small buffer for cohort transitions and missed-session makeups, that's roughly 12 protocol completions per year at steady state.
A monthly subscription cannot be honoured against this capacity. A subscription-style member could theoretically book chamber time anytime they liked; the chamber cannot accommodate that without breaking protocol commitments to other members. So HBOT is sold three ways — full protocol package (the headline product), 12-session block (the intermediate commitment), or single session (the drop-in entry point) — with full protocols taking priority on chamber capacity and singles fitting into gaps. The customer commits to a defined protocol with a confirmed start date; the chamber's availability is the constraint, and the product structure reflects that honestly.
Full 60-session clinical protocol — the headline product
£5,500 to £7,500 per protocol depending on whether pre/post bloodwork, biomarker baseline, and follow-up consultations are bundled. Five sessions per week for twelve weeks. Calibrated to the Efrati clinical protocol — the source of the telomere lengthening and senescent cell reduction findings that justify HBOT being on this proposition at all. Sold in cohort windows with confirmed start dates ("Spring 2026 cohort, March 17 to June 8, three places remaining") rather than always-on availability.
12-session block — intermediate commitment
£1,200 to £1,600 per block. For customers not ready for a full protocol commitment, returning customers topping up between protocols, or those completing a partial introduction during a residential programme stay and continuing locally. Typically delivered three sessions per week over four weeks, scheduled around protocol-customer chamber time rather than competing with it. Approximately 30 blocks per year at steady-state capacity.
Single sessions — drop-in and residential add-on
£125 to £175 per session. Two main use cases: residential programme guests (Long Week and Long View are the most likely uptake) buying an introduction during their stay, and local drop-in customers between protocol cohorts. Roughly 580 single sessions per year at steady state — the larger volume coming from residential add-on rather than local drop-in. Single sessions fit into chamber capacity gaps after protocols and blocks have first call.
Three customer profiles, three product formats.
The full protocol package is the headline product, sold to a Jersey resident or returning international customer who has decided to commit to the full Efrati protocol — typically a well-resourced individual aged 50+ who is paying explicitly for clinically-anchored longevity intervention with biomarker testing rather than for general-wellness sessions. The price point (£5,500 to £7,500) is meaningful but modest relative to comparable UK clinical HBOT centres (£4,000 to £10,000 for 60-session courses), and the full protocol is the only HBOT product where the literature supports the longevity claim being made.
The 12-session block sits between protocol commitment and casual use. Three typical buyers: customers building toward full protocol commitment who want to test their tolerance and scheduling realism before locking in twelve weeks; returning protocol customers maintaining sessions between full re-protocols (Efrati's protocol is typically repeated every 18–24 months for sustained effect); and residential programme guests who want to continue partial dosing locally after their stay introduces them to the chamber.
Single sessions are introduction and decision-support more than clinically-meaningful intervention. The literature does not support biomarker change from single sessions. They are sold for residential programme add-on use (a Long Week guest doing 5–7 sessions across the stay gets acute effects, familiarity with the chamber, and an informed decision about whether to pursue the full protocol) and for local drop-in customers who want to sample before committing to a block or protocol.
Variable margins are exceptional; chamber fixed costs are real.
HBOT pricing is anchored to UK comparables (clinical HBOT centres typically charge £150–250 per single session; specialist clinics offer 60-session courses at £4,000–10,000) and to the spec premium that 2.0+ ATA clinical-grade pressure justifies over the 1.3–1.5 ATA mild-HBOT chambers operated by other providers in Jersey. The Long Hotel's chamber would be the only clinical-grade unit on the island, sitting in a different market segment to wellness-HBOT operators rather than competing with them on price.
Variable margin per session
Per-session marginal cost is approximately £8 — £5 for medical-grade oxygen consumption and £3 for chamber maintenance allocation. The certified chamber operator's time is fixed cost (a salaried hire ramping from part-time in Year 1 to full-time from Year 3 once protocol cohorts are running concurrently) rather than per-session variable. Variable margins are exceptional: 91% on the full protocol (£6,500 average revenue against £580 variable cost), 91% on the 12-session block (£1,400 against £126), 95% on a single session (£150 against £8).
Chamber fixed opex is the binding cost line
The chamber's fixed annual opex ramps with utilisation: £30k in Year 1 (part-time operator, modest LN2 supply, baseline maintenance), £44k in Year 2, £73k in Year 3 once the operator goes full-time, ~£80k by Year 5 at mature volumes. This is real cost that the variable margins have to cover. At steady state (Year 5), HBOT revenue of approximately £207,000 against variable contribution of £192,000 (93% blended) and HBOT's allocated share of fixed opex (~70% of £80k = £56,000) produces approximately £99,000 net contribution from HBOT at Year 5, at 48% net margin.
Why the chamber needs both HBOT and cryo to be financeable
Neither HBOT nor cryo alone justifies the chamber operator's full-time hire from Year 3. HBOT's 12-protocol annual cap means revenue is capacity-limited even at full demand; cryo's revenue scales with member count, which Jersey's small population also constrains. Together, HBOT and cryo produce combined HBCR revenue of approximately £315,000 at Year 5 against combined chamber fixed opex of £80,000 — that's the configuration that makes the operator hire financeable. Committing one without the other is structurally weaker; the full case for committing both is on the Longevity page.
Why this is toggleable rather than committed by default
HBOT requires the monoplace chamber to be committed as Phase 02 capex — £55,000 to £85,000 of working capex, plus install, plus the certified-operator hire that becomes full-time by Year 3. Like the Cryo Add-on, this breaks the existing-infrastructure premise of the cornerstone Standard and Plus tiers. The full clinical case (the Efrati protocol literature, the equipment recommendations, the case for monoplace versus multi-place, the relationship with Viva at Strive, the Phase 02 commitment recommendation) is set out in detail on the Longevity page; this page focuses on the product structure and pricing.
How this fits the wider proposition.
HBOT Packages sit alongside the cornerstone clinical memberships and the Cryo Add-on as part of the Long Hotel architecture. The relationship is structural rather than overlapping — HBOT is not a clinical-membership tier and not a substitute for one; it is a parallel product the same customer might also buy.
Long Club Standard — the volume-tier clinical membership. Members may also buy HBOT protocols separately when committing to a 60-session course.
Long Club Plus — the flagship clinical membership. Plus members are the natural HBOT protocol customers: clinically-engaged, biomarker-tracking, willing to commit to a sustained course.
Cryo Add-on — whole-body cryotherapy at £150/month bolt-on or £180/month standalone. The other Phase 02 chamber product, sold as a daily-protocol membership rather than a package.
HBOT Packages — this product. £5,500–£7,500 per protocol, £1,200–£1,600 per 12-session block, £125–£175 per single session.
The full clinical case for HBOT (Efrati protocol literature, equipment recommendations, the relationship with Viva, the Phase 02 commitment argument) is on the Longevity page. The financial picture across the chamber and the wider membership architecture is on the Forecast page. To return to the membership overview, head back to the Membership page.